Device Trial Radar · NCT00406133
Randomized Study of Real-Time Continuous Glucose Monitors (RT-CGM) in the Management of Type 1 Diabetes
Last checked: Nov 20, 2026Latest source record: Apr 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
451
Actual
Start
Dec 2006
Primary completion
Jul 2008
Study completion Feb 2009
Sponsor
- Lead sponsor
- Jaeb Center for Health ResearchAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- JDRF Artificial Pancreas Project
- First posted
- Dec 4, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 8 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Subjects with intensively-treated type 1 diabetes and glycated hemoglobin (HbA1c) 7.0%-10.0% in 3 age groups (\>25, 15-24, 8-14) will be randomized to a continuous glucose monitoring (CGM) group or control group. The primary outcome is change in HbA1c after 26 weeks. A parallel randomized trial is being conducted for a second cohort with HbA1c \<7.0% that will follow an identical protocol to that of the first cohort with HbA1c \>=7.0%. The \>=7.0% trial was specifically designed and statistically powered to compare separately the impact of continuous versus standard intensive glucose monitoring in the three age groups. Both trials used standardized treatment algorithms and equivalent frequent contacts with subjects in both the CGM and control group. After completion of the 26-week trial, the CGM group continues to use CGM for another 26 weeks to evaluate whether any beneficial effect seen in the first 6 months is sustained with longer-term use and less intensive contact and the control group initiates CGM use with less intensive contact after the first month than was provided at initiation of CGM use in the CGM group in the randomized trial.
Conditions
- Type 1 Diabetes
Interventions
Continuous glucose monitorDevice
Daily use of a continuous glucose monitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Glycated Hemoglobin (HbA1c) From Baseline to 26 Weeks in the Continuous Glucose Monitoring (CGM) and Control Groups (for the Cohort With Baseline HbA1c >=7.0% Cohort)Time frame: Baseline and 26 weeks
- Time With Glucose Level <=70 mg/dL (for the Cohort With Baseline HbA1c <7.0%)Time frame: Baseline and 26 weeks
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
University of Southern California
Beverly Hills, California
Kaiser Permanente
San Diego, California
Stanford University
Stanford, California
8 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.